Table A4.
Results from sub-analysis with resulting risk ratios per analysis section.
| Subanalysis | Subjects with RTI | Monthly Risk of RTI | Overall Infections | Subjects with Recurrent RTI | Number of Recurrent RTI | Subjects with Complication | Number of Complications | Subjects with AB | Overall AB Days |
|---|---|---|---|---|---|---|---|---|---|
| Overall Result | 0.75 [0.69–0.81] I2 = 27% |
0.68 [0.61–0.77] I2 = 29% |
0.75 [0.69–0.82] I2 = 55% |
0.77 [0.68–0.88] I2 = 0% |
0.60 [0.46–0.80] I2 = 88% |
0.44 [0.36–0.54] I2 = 0% |
0.52 [0.43–0.64] I2 = 32% |
0.60 [0.39–0.93] I2 = 34% |
0.30 [0.12–0.73] I2 = 91% |
| Jadad Score ≥ 4 | 0.78 [0.71–0.86] I2 = 40% |
0.75 [0.64–0.87] I2 = 32% |
0.84 [0.80–0.88] I2 = 0% |
0.77 [0.68–0.88] I2 = 0% |
0.63 [0.46–0.87] I2 = 88% |
0.47 [0.37–0.58] I2 = 0% |
0.53 [0.41–0.68] I2 = 52% |
0.77 [0.34–1.45] I2 = 34% |
0.30 [0.12–0.73] I2 = 91% |
| Lipophilic Extracts | 0.75 [0.66–0.83] I2 = 47% |
0.66 [0.56–0.78] I2 = 50% |
0.72 [0.64–0.81] I2 = 68% |
0.63 [0.51–0.78] I2 = 0% |
0.53 [0.39–0.73] I2 = 72% |
0.46 [0.36–0.58] I2 = 0% |
0.42 [0.35–0.50] I2 = 0% |
0.45 [0.30–0.66] I2 = 0% |
0.30 [0.12–0.73] I2 = 91% |
| Hydrophilic Extracts | 0.79 [0.67–0.94] I2 = 0% |
0.75 [0.56–1.02] ns, 0% |
0.82 [0.66–1.02] ns, I2 = 15% |
0.80 [0.67–0.96] I2 = 0% |
0.87 [0.66–1.14] Ns, I2 = 0% |
0.26 [0.05–1.26] Ns, I2 = 0% |
0.68 [0.50–0.92] I2 = 0% |
1.14 [0.76–1.73] I2 = 0% |
No study providing data |
| Echinacea only | 0.80 [0.75–0.85] I2 = 0% |
0.78 [0.71–0.85] I2 = 0% |
0.79 [0.74–0.85] I2 = 7% |
0.77 [0.68–0.88] I2 = 0% |
0.80 [0.67–0.96] I2 = 16% |
0.47 [0.34–0.65] I2 = 0% |
0.64 [0.54–0.77] I2 = 0% |
0.73 [0.41–1.33] Ns, I2 = 26% |
0.21 [0.15–0.29] I2 = 0% |
Green 0–40% low heterogeneity. Rose 41–60% moderate heterogeneity. Light Red 61–75% substantial heterogeneity. Dark Red > 75% Considerable heterogeneity or non-significant result.